CN101490006B - 作为香草素-1受体调节剂的联芳基甲酸芳基酰胺 - Google Patents
作为香草素-1受体调节剂的联芳基甲酸芳基酰胺 Download PDFInfo
- Publication number
- CN101490006B CN101490006B CN200780025876XA CN200780025876A CN101490006B CN 101490006 B CN101490006 B CN 101490006B CN 200780025876X A CN200780025876X A CN 200780025876XA CN 200780025876 A CN200780025876 A CN 200780025876A CN 101490006 B CN101490006 B CN 101490006B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- capsicine
- phenyl
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010025083 TRPV1 receptor Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 208000004296 neuralgia Diseases 0.000 claims abstract description 3
- 208000021722 neuropathic pain Diseases 0.000 claims abstract description 3
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 5
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 12
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 238000013016 damping Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 208000004454 Hyperalgesia Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000003594 spinal ganglia Anatomy 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- ZDKRADGNGVIHQR-UHFFFAOYSA-N 6-chloro-n-(4-chlorophenyl)pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=C(Cl)N=C1 ZDKRADGNGVIHQR-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- PJAAESPGJOSQGZ-DZGBDDFRSA-N Isovelleral Chemical compound O=CC1=C[C@@H]2CC(C)(C)C[C@@H]2[C@@]2(C)C[C@]21C=O PJAAESPGJOSQGZ-DZGBDDFRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- 229940126422 TRPV1 antagonist Drugs 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010053552 allodynia Diseases 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 3
- -1 triisopropyl borate ester Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 235000001427 Cylindropuntia imbricata Nutrition 0.000 description 2
- 240000005729 Cylindropuntia imbricata Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229930195722 L-methionine Natural products 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- 244000263375 Vanilla tahitensis Species 0.000 description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 0 *c1cccc2c1ccnc2 Chemical compound *c1cccc2c1ccnc2 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- CYJZJGYYTFQQBY-UHFFFAOYSA-N 5-bromoisoquinoline Chemical compound N1=CC=C2C(Br)=CC=CC2=C1 CYJZJGYYTFQQBY-UHFFFAOYSA-N 0.000 description 1
- SNMZXTXZEQGKBG-UHFFFAOYSA-N 6-bromopyridine-3-carboxamide Chemical compound NC(=O)C1=CC=C(Br)N=C1 SNMZXTXZEQGKBG-UHFFFAOYSA-N 0.000 description 1
- FMEBIWNKYZUWFV-UHFFFAOYSA-N 6-chloropyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)N=C1 FMEBIWNKYZUWFV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010065952 Hyperpathia Diseases 0.000 description 1
- 101100404651 Mus musculus Ngf gene Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- MIYFJEKZLFWKLZ-UHFFFAOYSA-N Phenylmethyl benzeneacetate Chemical compound C=1C=CC=CC=1COC(=O)CC1=CC=CC=C1 MIYFJEKZLFWKLZ-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000011040 TRPV Cation Channels Human genes 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 239000000085 vanilloid receptor antagonist Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
本发明涉及式(I)化合物，其中A和Z如说明书中所定义，还涉及制备这些衍生物的方法以及它们用于治疗炎性疾病如神经性疼痛的用途。
Description
发明领域
本发明涉及香草素受体调节剂，特别是涉及TRPV1拮抗剂。
背景技术
瞬时受体电位香草酸亚型1(TRPV1)与温度和机械性痛觉过敏的发生密切相关，且已提出其在包括神经性疼痛和泌尿障碍的不同的病理状况中起关键作用。
包含联芳基部分的香草素受体拮抗剂是已知的；其中，在WO2004/0567741中公开了以下被取代的联芳基-4-甲酸芳基酰胺：
发明描述
现在已发现通过用异喹啉-5-基环替换以上化合物中的吡啶基可得到具有改良的特性的TRPV1拮抗剂。
相应地，本发明提供了改良的通式(I)的香草素-1受体调节剂
其中：
A是CH或N；
Z是苯基或吡啶基环，其任选地被1或2个R基团取代，所述R基团彼此可以相同或不同且选自C1-C4烷基(优选地是甲基、异丙基或叔丁基)、C1-C4卤代烷基(优选地是三氟甲基)或卤素。
在本说明书中，卤素是指选自氟、氯、溴和碘的卤原子，优选地是氯。
本发明优选的第一组化合物是式(Ia)的化合物，
其中Z如上文所定义。
本发明优选的第二组化合物是式(Ib)的化合物，
其中Z如上文所定义。
在式(Ia)和式(Ib)的化合物中，Z优选地是在对位被除氢以外、优选地是氯的R基团取代的苯环。本发明最优选的化合物是N-(4-氯苯基)-6-(异喹啉-5-基)吡啶-3-甲酰胺(下文用V394表示)。
式(I)化合物可用常规方法制备，如通过将式(II)化合物，
其中A如上文所定义且将羧基活化为酰氯，
和式(III)化合物反应来制备，
Z-NH2
(III)
其中Z如上文所定义。
优选地，式(I)化合物可通过将式(IV)化合物，
其中A和Z如上文所定义且X是选自碘和溴的卤素，
和硼酸(V)进行Suzuki反应2来得到
例如，将6-溴-或6-氯-N-(4-氯苯基)吡啶-3-甲酰胺和异喹啉-5-基-5-硼酸进行Suzuki反应可方便地制备化合物V394。
式(I)化合物调节TRPV1受体；优选的化合物V394在大鼠脊髓中的Ki值为15nM(13-17)，且在培养的大鼠背根神经节神经元中的IC50值为0.83nM(0.74-0.93)。因此，本发明的化合物可用于制备治疗炎性状态(如慢性疼痛和炎性痛觉过敏)的药物组合物。这些制剂可以通过常规的方法和赋形剂来制备，例如在Remington’s药学手册(Pharmaceutical ScienceHandbook)，XVII版，Mack Pub.，N.Y.，U.S.A.中所公开的内容。
将通过以下实施例在下文中阐明本发明。
实施例
材料和方法
所有可商购的化合物均从Aldrich购得且未经进一步纯化直接使用。反应进程通过硅胶薄层色谱(预涂覆F254Merck板)监测，斑点用紫外光检测并用KMnO4水溶液显色。快速色谱使用Merck硅胶(230-240目)进行。1H-NMR谱以TMS为内标通过Varian 400MHz波谱仪记录。质谱通过Waters-Micromass ZMD质谱仪获得。熔点通过Buchi-Tottoli仪器确定且未经校正。
实施例N-(4-氯苯基)-6-(异喹啉-5-基)吡啶-3-甲酰胺(V394)
步骤a)6-氯-N-(4-氯苯基)吡啶-3-甲酰胺
将商购可得的6-氯-烟酰氯(56.8mmol，10g)溶于50ml无水CH2Cl2中，并在0℃将其滴加到二异丙基胺(DIEA)(1.2当量，68.2mmol，11.67ml)和4-氯苯胺(1.2当量，68.2mmol，8.70g)的50ml CH2Cl2溶液中。在室温下将该混合液搅拌20小时，然后用CH2Cl2(200ml)稀释并用水(1x200ml)和盐水(1x100ml)洗涤。用硫酸钠干燥有机层并将其浓缩。使粗产物从乙醚中结晶，得到13g白色固体。收率＝86％。1H NMR(CDCl3，200MHz)δ7.35(2H，d，J＝8.8Hz)，7.47(1H，d，J＝8.2Hz)，7.58(2H，d，J＝8.8Hz)，7.88(1H，bs)，8.16(1H，dd，J＝8.4Hz，J’＝2.8Hz)，8.84(1H，d，J＝2.4Hz)。
步骤b)异喹啉-5-基-5-硼酸
将冷却至-78℃的n-BuLi(1.2当量，3mmol，1.2ml)在20ml新蒸馏THF中的2.5M的溶液加入到5-溴异喹啉(2.5mmol，520mg)的5ml THF溶液中。使得到的混合液在此温度下反应45分钟。然后加入硼酸三异丙酯(1.2当量，3mmol，0.7ml)的溶液并在相同温度下搅拌混合液5分钟，然后使其升至室温并再搅拌一个小时。通过缓慢加入5％NaOH溶液(30ml)淬灭混合液。分离水层并在0℃加入10％HCl将其酸化至pH值5/6。用乙酸乙酯萃取，蒸发有机相，并使其从乙醚中结晶，得到250mg白色固体。收率＝58％。1H NMR(d6-DMSO，200MHz)δ7.66(1H，t，J＝7.2Hz)，8.07(1H，d，J＝5.8Hz)，8.13(1H，d，J＝8.0Hz)，8.34(1H，d)，8.47(1H，d)，8.50(2H，bs)，9.29(1H，s)；[M+1]174.1(C9H8BNO2计算值172.98)。
步骤c)N-(4-氯苯基)-6-(异喹啉-5-基)吡啶-3-甲酰胺(Suzuki反应)
将异喹啉-5-基-5-硼酸(1.5当量，8.4mmol，1.46g)、6-氯-N-(4-氯苯基)吡啶-3-甲酰胺(5.6mmol，1.5g)、醋酸钯(4％mol，48mg)、三苯基膦(2当量，2.94g)、15％Na2CO3(4ml)、EtOH(4ml)和甲苯(50ml)的混合液在80℃加热16小时。蒸发后，加入饱和的碳酸氢钠溶液并滤出沉淀的固体，然后用乙酸乙酯洗涤。使残余物从甲醇中重结晶，得到1.4g白色固体状的化合物V394。熔点(乙醚)＝258℃。收率＝69％。1H NMR(d6-DMSO，400MHz)δ7.471(2H，d，J＝8.8Hz)，7.838(1H，m)，7.852(2H，d，J＝8.8Hz)，7.953(1H，d，J＝8.0Hz)，8.049(1H，dd，J＝7.2Hz，J’＝0.8Hz)，8.085(1H，d，J＝6.0Hz)，8.290(1H，d，J＝8.4Hz)，8.490(1H，dd，J＝8.4Hz，J’＝2.2Hz)，8.543(1H，d，J＝6.0Hz)，9.300(1H，d，J＝1.6Hz)，9.438(1H，s)，10.695(1H，s)；[M+1]360.4(C21H14ClN3O计算值359.81)。
生物学试验
使用新生和成年的Sprague-Dawley大鼠(～250g)(意大利，Harlam)。所有试验均遵循国家指南并经地区伦理委员会批准。
放射性配体结合试验
使用试验时重量在250至350g之间的雄性Sprague-Dawley大鼠。对于结合试验而言，断头处死麻醉的大鼠，取出脊髓，并将其在冰冷的包含5mM KCl、5.8mM NaCl、0.75mM CaCl2、2mM MgCl2、320mM蔗糖、10mM Hepes的缓冲液(pH 8.6)中用Polytron组织匀浆机进行破碎5。将匀浆过的组织在4℃以1000xg离心10分钟，将上清液在4℃以35000xg再离心30分钟(Beckman Avanti J25)。将沉淀物用上述同样的缓冲液重悬并用于结合试验中。在饱和实验中，将来自膜悬浮液的150μg蛋白质/样品与[3H]-仙人掌毒素([3H]-RTX)(0.003-3nM)在包含0.25mg/ml无脂肪酸牛血清白蛋白的试验缓冲液中在37℃孵育60分钟。在竞争试验中，将膜、[3H]RTX(0.4nM)和浓度增加(从0.1nM至3μM)的测试化合物在37℃孵育60分钟。
在1μM RTX的存在下评价非特异性结合。孵育后将反应混合液在0℃冷却，并与牛α1-酸糖蛋白(200μg每管)孵育15分钟以减少非特异性RTX结合。通过将样品在18500xg离心15分钟使膜结合的RTX与游离RTX分离。切下微量离心管带有沉淀的离心管的尖端部分，并通过闪烁计数(Packard 2500 TR)测量其放射性活度。依据Bio-Rad方法以牛血清白蛋白作为标准参照物测定蛋白质浓度(Bradford，1976)。用Ligand程序分析饱和与竞争试验6。
培养的大鼠背根神经节神经元中的Ca2+荧光测定
将成年大鼠末梢麻醉并断头处死。取出背根神经节并将其置于冷的磷酸盐缓冲液(PBS)中，然后转移至胶原酶(10mg/ml)、胰蛋白酶(5mg/ml)和DNAse(1mg/ml)中于37℃放置35分钟。通过用一系列注射器针头(由23G降至25G)吹打若干次，将放置在冷的DMEM(补充有10％胎牛血清、2mM L-谷氨酰胺、100U/ml青霉素和100μg/ml链霉素)中的神经节分离成单个细胞。过滤培养基和神经节以除去组织碎片，向其中注满8mlDMEM培养基并离心(200xg 5分钟)。将最终的细胞沉淀重悬于DMEM培养基(补充有100ng/ml小鼠神经生长因子(小鼠-NGF-7S)和胞嘧啶-β-d-阿糖胞苷游离碱(ARA-C)2.5μM)中。将细胞铺于涂覆聚L-赖氨酸(8.3μM)和层粘连蛋白(5μM)的25mm的盖玻片上，在37℃于充有5％CO2和空气的加湿培养箱中培养5-8天，然后加入在Ca2+缓冲液(具有以下成分(mM)：CaCl2 1.4、KCl 5.4、MgSO4 0.4、NaCl 135、D-葡萄糖5、HEPES10含BSA(0.1％)，pH 7.4)中的Fura-2-AM-ester(3μM)，于37℃放置40分钟。然后用Ca2+缓冲液洗涤细胞两次并转移至Nikon Eclipse TE300倒置显微镜的台上的槽中。在340nM和380nM激发Fura-2-AM-ester，通过用动态图像分析系统(Laboratory Automation 2.0，RCS，意大利，佛罗伦萨)计录F340/F380比值以指示相对[Ca2+]i变化，在该实验开始前使细胞(至少10分钟)达到稳定的荧光。用含Fura-2-AM-ester和确定浓度的游离Ca2+的缓冲液制作标准曲线。然后用该曲线将由F340/F380比值得到的数据转化为[Ca2+]i(nM)8。研究用抗辣椒碱(CPZ)、SB366791和V394进行预处理对由0.1μM辣椒碱产生的[Ca2+]i增加的影响。
大鼠中由辣椒碱-诱导的继发的异常性疼痛
在乙醚麻醉的大鼠右爪光滑皮肤的跖面注射辣椒碱(20nmols/50μl/爪)(Chaplan等人，1994)。在注射辣椒碱前两小时口服施用化合物V394(30μmol/kg)。辣椒碱刺激90分钟后评价触觉异常性疼痛。
药物和试剂
药物和试剂从所标明的公司购得：[3H]-仙人掌毒素(Perkin Elmer，Boston，MA)、SB-366791(Tocris，UK)、辣椒碱、抗辣椒碱、离子霉素、层粘连蛋白、聚L-赖氨酸、P物质(Sigma，意大利)；小鼠NGF-7S和胶原酶/分散酶(Roche Diagnostics，意大利)；达尔伯克改良伊格尔培养基(DMEM)、热灭活的胎牛血清(FBS)、L-谷氨酰胺(200mM)、青霉素/链霉素(10,000IU/ml±10,000UG/ml)(Gibco，意大利)；Fura-2-AM-ester(SocietàItaliana Chimici，意大利)。在50％DMSO和50％吐温80中配制辣椒碱(10mM)、抗辣椒碱(10mM)、(E)-3-(4-氯苯基)-N-(3-甲氧基苯基)丙烯酰胺(称为SB-366791)(1mM)和V394的储备液浓度。将Fura-2-AM-ester和离子霉素溶于100％的DMSO。将所有其它药物溶于蒸馏水。然后在Krebs缓冲液中配制到适合的稀释度。
结果
放射性配体结合试验
[3H]-RTX对大鼠脊髓表达的TRPV1的饱和曲线显示KD值为0.21(0.16-0.27)且Bmax值为57(53-62)fmol/mg蛋白质。斯卡查德图基本上呈线性且对数据进行的计算机分析表明只存在一类的高亲和性的结合位点。[3H]-RTX的竞争结合试验表明V394和对照SB-366791的Ki值分别为15(13-17)nM和36(30-43)nM。
Ca2+荧光
在绝大多数(95％)的背根神经节神经元中辣椒碱(0.1μM)均引起[Ca2+]增加，由此可确定这些背根神经节神经元为TRPV1表达神经元。抑制由辣椒碱诱导的[Ca2+]i活化的V394的IC50值为0.83nM(0.74-0.93)。抗辣椒碱和SB-366791(对照的TRPV1拮抗剂)抑制辣椒碱响应的IC50值分别为948(676-1330)nM和8.7(3.4-17.3)nM。该结果表示为平均值和95％的置信区间。
大鼠中由辣椒碱-诱导的继发的异常性疼痛
辣椒碱刺激90分钟后，化合物V394对辣椒碱的促异常性疼痛作用有显著的预防作用(55％)。
参考文献
1.Bakthavatchalam，R.；Blum，C.A.；Brielmann，H.；Darrow，J.W.；DeLombaert，S.；Yoon，T.；Zheug，X.Neurogen Corporation WO2004/056774，170pp。
2.Shieh，W.C.；Carlson，J.A.J.Org.Chem.1992，57，379-381。
3.Zhang，J.；Assodi，J.；Charter，C.；L′hermite，N.；Weston，J.Tetrahedron Lett.2001，42，6683-6686。
4.Meier，P.；Legraverant，S.；Mueller，S.；Schaub，J.Synthesis 2003，4，551-554。
5.a)Szallasi A.和Blunberg P.M.Neurosciences 1992，8，368。b)Szallasi A.和Blunberg P.M.Naunyn Schmiedeberg’s Arch Pharmacol.1993，347，84-91。
6.Munson，P.J.；Rodbard，D.Anal.Biochem.1980，107，220-239。
7.Rigoni，M.；Trevisani，M.；Gazzieri，D.；Nadaletto，R.；Tognetto，M.；Creminon，C.；Davis，J.B.；Campi，B.；Amatesi，S.；Geppetti，P.；Harrison，S.Br.J.Pharmacol.2003，138，977-985。
8.Kudo，Y.；Ozaki，K.；Miyakawa，A.；Amano，T.；Ogura，A.Jap.J.Pharmacol.1986，41，345-351。
Claims (8)
1.通式(I)的化合物
其中：
A是CH或N；
Z是苯基或吡啶基环，其任选地被1或2个R基团取代，所述R基团彼此可以相同或不同且选自C1-C4烷基、C1-C4卤代烷基或卤素。
2.根据权利要求1的化合物，其中R选自甲基、异丙基、叔丁基或三氟甲基。
3.式(Ia)的根据权利要求1的化合物
其中Z如权利要求1所定义。
4.式(Ib)的根据权利要求1的化合物
其中Z如权利要求1所定义。
5.下式的根据权利要求4的化合物：
6.权利要求1至5中任意一项的化合物在制备用于治疗炎性疾病和泌尿障碍的药物中的用途。
7.根据权利要求6的用途，其中炎性疾病是神经性疼痛。
8.包含权利要求1至5中任意一项的化合物和可药用载体和/或赋形剂的药物组合物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06014302A EP1889830A1 (en) | 2006-07-10 | 2006-07-10 | Biarylcarboxyarylamides as vanilloid-1 receptor modulators |
| EP06014302.1 | 2006-07-10 | ||
| PCT/EP2007/005835 WO2008006480A1 (en) | 2006-07-10 | 2007-07-02 | Biarylcarboxyarylamides as vanilloid-1 receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101490006A CN101490006A (zh) | 2009-07-22 |
| CN101490006B true CN101490006B (zh) | 2012-05-23 |
Family
ID=37433925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200780025876XA Expired - Fee Related CN101490006B (zh) | 2006-07-10 | 2007-07-02 | 作为香草素-1受体调节剂的联芳基甲酸芳基酰胺 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8222275B2 (zh) |
| EP (2) | EP1889830A1 (zh) |
| JP (1) | JP5166412B2 (zh) |
| CN (1) | CN101490006B (zh) |
| AT (1) | ATE514679T1 (zh) |
| BR (1) | BRPI0713988A2 (zh) |
| CA (1) | CA2657300A1 (zh) |
| ES (1) | ES2366240T3 (zh) |
| MX (1) | MX2009000366A (zh) |
| RU (1) | RU2468020C2 (zh) |
| WO (1) | WO2008006480A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2048133A1 (en) * | 2007-10-04 | 2009-04-15 | Pharmeste S.r.l. | Nicotinamide n-oxide derivatives as vanilloid-1 receptor modulators |
| CN107522669B (zh) * | 2017-08-24 | 2019-12-03 | 重庆美莱德生物医药有限公司 | 瞬时受体电位香草酸亚型1拮抗剂及其制备方法和用途 |
| CN107522668B (zh) * | 2017-08-24 | 2019-12-03 | 重庆医科大学 | Trpv1拮抗剂及其制备方法和用途 |
| RU2755206C1 (ru) | 2020-05-20 | 2021-09-14 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство пролонгированного анальгетического действия и лекарственный препарат на его основе |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004056774A2 (en) * | 2002-12-19 | 2004-07-08 | Neurogen Corporation | Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
| CN1553905A (zh) * | 2001-09-13 | 2004-12-08 | ʷ | 可作为香草素受体拮抗剂用于治疗疼痛的脲类化合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0212607A (pt) | 2001-09-18 | 2004-08-17 | Hoffmann La Roche | Agonistas retinóides ii de uréia substituìda |
| CA2468544A1 (en) | 2001-12-10 | 2003-06-19 | Amgen Inc. | Vanilloid receptor ligands |
| TWI319387B (en) * | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| EP1889837A1 (en) | 2006-07-10 | 2008-02-20 | Pharmeste S.r.l. | VR1 vanilloid receptor antagonists with a iononic substructure |
-
2006
- 2006-07-10 EP EP06014302A patent/EP1889830A1/en not_active Withdrawn
-
2007
- 2007-07-02 US US12/307,921 patent/US8222275B2/en not_active Expired - Fee Related
- 2007-07-02 AT AT07764992T patent/ATE514679T1/de not_active IP Right Cessation
- 2007-07-02 EP EP07764992A patent/EP2041094B1/en active Active
- 2007-07-02 MX MX2009000366A patent/MX2009000366A/es unknown
- 2007-07-02 JP JP2009518747A patent/JP5166412B2/ja not_active Expired - Fee Related
- 2007-07-02 RU RU2008152764/04A patent/RU2468020C2/ru not_active IP Right Cessation
- 2007-07-02 BR BRPI0713988-8A patent/BRPI0713988A2/pt not_active IP Right Cessation
- 2007-07-02 CN CN200780025876XA patent/CN101490006B/zh not_active Expired - Fee Related
- 2007-07-02 WO PCT/EP2007/005835 patent/WO2008006480A1/en active Application Filing
- 2007-07-02 CA CA002657300A patent/CA2657300A1/en not_active Abandoned
- 2007-07-02 ES ES07764992T patent/ES2366240T3/es active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1553905A (zh) * | 2001-09-13 | 2004-12-08 | ʷ | 可作为香草素受体拮抗剂用于治疗疼痛的脲类化合物 |
| WO2004056774A2 (en) * | 2002-12-19 | 2004-07-08 | Neurogen Corporation | Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2008152764A (ru) | 2010-07-20 |
| EP1889830A1 (en) | 2008-02-20 |
| CN101490006A (zh) | 2009-07-22 |
| ATE514679T1 (de) | 2011-07-15 |
| BRPI0713988A2 (pt) | 2012-11-20 |
| JP2009542738A (ja) | 2009-12-03 |
| EP2041094B1 (en) | 2011-06-29 |
| EP2041094A1 (en) | 2009-04-01 |
| CA2657300A1 (en) | 2008-01-17 |
| US20100081687A1 (en) | 2010-04-01 |
| WO2008006480A1 (en) | 2008-01-17 |
| MX2009000366A (es) | 2009-03-09 |
| ES2366240T3 (es) | 2011-10-18 |
| JP5166412B2 (ja) | 2013-03-21 |
| US8222275B2 (en) | 2012-07-17 |
| RU2468020C2 (ru) | 2012-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101490007B (zh) | 具有芷香酮亚结构的vr1香草素受体拮抗剂 | |
| AU2014232383B2 (en) | Heterocyclic compounds useful in the treatment of disease | |
| EP2443123B1 (en) | Small molecule inhibitors of spleen tyrosine kinase (syk) | |
| TW201906825A (zh) | 化合物及其使用方法 | |
| BRPI0716888A2 (pt) | Composto, composição farmacêutica, composição farmacêutica embalada, método para tratamento de um paciente, método para aumentar a sensibilidade de células cancerosas a quimioterapia, método de redução do erro medicamentoso, método para inibição da hidrólise de atp, método para a determinação da presença de btk em uma amostra, método para a inibição da atividade de células b e uso do composto ou composição. | |
| CN101490006B (zh) | 作为香草素-1受体调节剂的联芳基甲酸芳基酰胺 | |
| Rühl et al. | Cannabinoid receptor type 2 (CB2)-selective N-aryl-oxadiazolyl-propionamides: synthesis, radiolabelling, molecular modelling and biological evaluation | |
| KR20040015716A (ko) | Ｃｒｆ1 조절자로서의 5-치환된-2-아릴피리딘 | |
| CN103781751A (zh) | 用作雌激素受体β的调节剂的二苯基取代的环己烷衍生物 | |
| Li et al. | Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors | |
| US20200216435A1 (en) | Bicyclic heteroaromatic amide compounds for use in therapy | |
| He et al. | Identification of new dual FABP4/5 inhibitors based on a naphthalene-1-sulfonamide FABP4 inhibitor | |
| US9617226B2 (en) | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases | |
| Hernandez-Olmos et al. | First Structure–Activity Relationship Study of Potent BLT2 Agonists as Potential Wound-Healing Promoters | |
| WO2022099044A1 (en) | 2-pyridones as thyroid hormone receptor modulators | |
| Kim et al. | Efficient discovery of selective small molecule agonists of estrogen-related receptor γ using combinatorial approach | |
| Vázquez et al. | Synthesis of novel pyrazole derivatives incorporating one dicarba-closo-dodecaborane unit | |
| EP1560822B1 (en) | 4-imidazol-1-ylmethyl-pyrimidine derivatives as ligands for gabaa receptors | |
| Hu et al. | Synthesis and functional characterization of substituted isoquinolinones as MT2-selective melatoninergic ligands | |
| CN108586432B (zh) | 一种3-(吲哚-5-基)-吲唑衍生物及其应用 | |
| WO2024137358A1 (en) | Kdm1a inhibitors for the treatment of disease | |
| Trabbic | Chemoenzymatic synthesis of NAADP derivatives: probing the unknown NAADP receptor | |
| BR112017004868B1 (pt) | Derivados de pirrolopirimidina como antagonistas do receptor nmda nr2b e composição farmacêutica que os compreende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120523 Termination date: 20140702 |
|
| EXPY | Termination of patent right or utility model |